Latest Partnerships News

Hastings Technology Metals appoints Vince Catania as CEO, entrusting him with advancing the Yangibana Rare Earths Project and broader portfolio development.

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

Asara Resources has received a significant cash payment from Teck Resources Chile following the resolution of a legal dispute, marking a key milestone in their joint venture for the Loreto Copper Project.

DigitalX Limited's treasury reached a record A$75.9 million in May 2025, propelled by increased Solana holdings and enhanced staking yields. The company’s innovative approach balances Bitcoin’s stability with yield-generating digital assets.

Service Stream Limited has locked in a significant $440 million contract with NBN Co to continue upgrading Australia’s fibre network, extending its role in the national infrastructure program.

Noxopharm’s Sofra™ technology has received promising external validation from BioRay Pharmaceutical, confirming its targeted anti-inflammatory potential and broad applicability in autoimmune disease therapies.

Cokal Limited has secured US$15 million in strategic debt funding to ramp up metallurgical coal production at its BBM mine, while terminating all agreements with Cratus due to non-performance.

Bastion Minerals has confirmed it is finalising a JORC Mineral Resource Estimate for its ICE Copper Gold Project, explaining recent sharp price and volume movements in its shares. The company plans to announce the estimate by June 10, 2025.

Iceni Gold has raised $2.5 million in an oversubscribed placement to fund key drilling programs at its 14 Mile Well Gold Project and initiate exploration at the Welcome Creek copper-gold target in Western Australia.

Olympus Corporation has launched a nationwide emphysema screening campaign in the US powered by 4DMedical’s AI lung density analysis, marking a major commercial milestone for the Australian medtech firm.

Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.

Fletcher Building has confirmed it is fielding inquiries from potential buyers following its strategic review announcement, though no sales decisions have been made. Investors await clarity at the upcoming Investor Day.